TSTsung-Hua Shen

Tsung-Hua Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tsung-Hua Shen has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Joel F. Farley

    Department of Pharmaceutical Care & Health Systems College of Pharmacy, University of Minnesota Minneapolis Minnesota USA

    2 shared publications
  • Chun-Chao Chang

    Taipei Medical University Hospital

    1 shared publication
  • Chung-Hsuen Wu

    Taipei Medical University School of Pharmacy: Taipei Medical University College of Pharmacy

    1 shared publication
  • David D. Stenehjem

    College of Pharmacy, University of Utah, Salt Lake City, UT, USA.

    1 shared publication
  • David Vock

    Division of Biostatistics & Health Data Science, School of Public Health University of Minnesota Minneapolis Minnesota USA

    1 shared publication
  • Elizabeth S. Aby

    Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition University of Minnesota Minneapolis Minnesota USA

    1 shared publication

Latest Publications

  • Health care utilization and spending following comprehensive medication review in Medicare part D

    by Shaquib Al Hasan, Tsung-Hua Shen, Felix Cheuk Wun Ting, Joel F. Farley

  • Open Access

    Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease

    by Tsung‐Hua Shen, Elizabeth S. Aby, David Vock, Joel F. Farley

    Aim: To compare the effectiveness of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) with dipeptidyl peptidase‐4 inhibitors (DPP4is) on major liver outcomes (MLO) in patients with type 2 diabetes (T2D) and metabolic dysfunction‐associated steatotic liver disease (MASLD). Materials and Methods: We included adult patients with T2D and MASLD, using metformin without specific liver conditions or surgeries, from the Merative MarketScan database. Patients initiating SGLT2is or DPP4is from 1 January 2014 to 31 December 2022 were identified. The primary outcome was time to MLO diagnosis. Overlap weighting balanced covariates, integrated with a Cox proportional hazards model for survival analysis. Results: Among 44 651 patients, 22 100 initiated SGLT2is, and 22 551 began DPP4is. After weighting, the incidence rate of MLO in the SGLT2i group was 3.8 per 1000 person‐years, and it was 3.9 per 1000 person‐years in the DPP4i group, resulting in an adjusted hazard ratio (aHR) of 0.82 (95% CI, 0.60‐1.10). SGLT2i initiation was not associated with cirrhosis (aHR: 0.77; 95% CI, 0.55‐1.06) or hepatocellular carcinoma (aHR: 0.99; 95% CI, 0.47‐1.83) separately. Subgroup and sensitivity analyses did not yield significant results. Conclusions: In patients with T2D and MASLD, SGLT2is did not show a lower risk of MLO compared with DPP4is. Clinicians should consider the overall patient conditions and the additional benefits of SGLT2is to support the decision to switch from DPP4is.


  • Open Access

    High rifaximin out-of-pocket costs are associated with decreased treatment retention among patients with hepatic encephalopathy

    by Elizabeth S. Aby, Tsung-Hua Shen, Meena N. Murugappan, David D. Stenehjem, Thomas M. Leventhal

    Background and Aims: Hepatic encephalopathy (HE) is associated with significant morbidity and mortality for those with cirrhosis. Despite the known benefits of rifaximin use for HE, treatment retention remains low. This study aimed to evaluate the impact of out-of-pocket (OOP) rifaximin cost on treatment retention among commercially insured patients in the United States. Methods: Adult patients with cirrhosis and HE were identified from the IBM MarketScan claims database. Those who began rifaximin treatment between January 1, 2011, and December 1, 2021 were included. Regression models were used to analyze the relationship between patients’ 30-day OOP rifaximin cost and rifaximin retention (≥80% eligible days with rifaximin supply) at 180, 360, and 540 days. Models were controlled for patient demographic and clinical characteristics including age, sex, comorbid conditions, Charlson comorbidity index (CCI), and lactulose use. Results: A total of 6839 adult patients were included. Most patients were between 55 and 64 years (57.1%), male (60.4%), and living in urban settings (84.6%). Treatment retention was low for all time periods; retention rates for rifaximin were 42%, 25%, and 16% at 180, 360, and 540 days, respectively. In multivariable analysis, 30-day OOP costs of ≥ $150 were associated with a decreased likelihood of rifaximin retention at 180, 360, and 540 days [relative risk (RR) = 0.67, RR = 0.62, and R = 0.60, respectively]. Younger age was associated with reduced treatment retention for all time periods. Metastatic cancer and depression were associated with reduced treatment retention at 180 days (RR = 0.70 and RR = 0.87, respectively). Conclusions: Rates of rifaximin treatment retention are low despite the known benefits of rifaximin use for breakthrough HE. High 30-day OOP cost is associated with reduced rifaximin treatment retention. Export


  • Open Access

    Prevalence, Trends, and Characteristics of Nonalcoholic Fatty Liver Disease among the US Population Aged 12–79 Years

    by Tsung-Hua Shen, Chung-Hsuen Wu, Yuan-Wen Lee, Chun-Chao Chang

    Background & Aims: Clinical observation revealed an increase in nonalcoholic fatty liver disease (NAFLD) prevalence among adults and adolescents and young adults (AYA). However, its prevalence trend in specific subgroups and its characteristics are unclear. Approach & Results: This cross-sectional study included adults and AYA aged 20–79 and 12–19 years, respectively, from the National Health and Nutrition Examination Survey from 1999 to 2018. NAFLD was defined as US Fatty Liver Index ≥ 30 in adults and alanine amino transaminase elevation and obesity in AYA. Joinpoint and logistic regression were used to evaluate the NAFLD prevalence trend and its associated characteristics. NAFLD was diagnosed in 17,156,892 of 51,109,914 (33.6%) adults and 1,705,586 of 29,278,666 AYA (5.8%). During the study period, NAFLD prevalence significantly increased from 30.8–37.7% (P < 0.01) in adults and in subgroups of female participants, individuals aged 20–45 and 61–79 years, and non-Hispanic white individuals. Conversely, NAFLD prevalence did not significantly change in AYA (from 5.1–5.2%, P = 0.139), except in the subgroup of Mexican Americans (from 8.2–10.8%, P = 0.01). Among adults, high NAFLD prevalence was associated with male sex, Mexican American ethnicity, age > 50 years, being unmarried, poverty income ratio < 130, poor or fair health condition, obesity or overweight, and chronic conditions. Among AYA, high NAFLD prevalence was associated with male sex, poverty income ratio < 130, and education. Conclusions: Accordingly, we concluded that health care providers should prevent and treat conditions associated with NAFLD by raising awareness of the increasing trend of NAFLD.